CAMBRIDGE, Mass.--( BUSINESS WIRE)--City Therapeutics, Inc. (City), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced the appointments of Keith Regnante, MBA, as Chief Financial Officer, and Mary Beth DeLena, J.D., as
Viking Global Investors and Sofinnova Investments join a strong syndicate of existing investors including ARCH Venture Partners, Fidelity Management & Research Company and Invus Proceeds to accelerate the company’s RNAi engineering platform and pipeline, including ongoing Phase 1 clinical trial of
Data demonstrate potent, durable RNAi-mediated silencing of retinol binding protein 4 (RBP4) with reduced toxic retinoid accumulation, a key driver of the rare inherited retinal disease CAMBRIDGE, MA, May 6, 2026 – City Therapeutics, Inc., a biopharmaceutical company leading the future of RNA
